CLINICAL SCIENCE Subconjunctival Bevacizumab Injection

in patients with corneal neovascularization. Methods: The charts of 10 consecutive patients with corneal neovascularization who received subconjunctival injections of bevacizumab (2.5 mg/0.1 mL) were reviewed. Digital photographs of the cornea were graded by 2 masked observers for density, extent, and centricity of corneal vascularization. Image analysis was used to determine the area of cornea covered by neovascularization as a percentage of the total corneal area. Results: No significant ocular or systemic adverse events were ob-served during 3.5 6 1.1 months of follow-up. Seven patients showed partial regression of vessels. The extent decreased from 6.0 6 1.2 (SD) clock hours before the injection to 4.6 6 1.0 clock hours after bevacizumab injection (P = 0.008). Density decreased from 2.76 0.2 to 1.9 6 0.3, respectively. (P = 0.007). No change was noticed in the centricity of corneal vessels. Corneal neovascularization covered, on average, 14.8 % 6 2.5 % (SD) of the corneal surface before the injections, compared with 10.5 % 6 2.8 % (P = 0.36, t test) after bevacizumab injection. Therefore, bevacizumab decreased corneal neovascularization by 29%. Conclusions: Short-term results suggest that subconjunctival bevacizumab is well tolerated and associated with a partial regression of corneal neovascularization